N. Roche (Paris, France), D. Price (Cambridge, United Kingdom), F. Ducharme (Montreal, Canada), W. Anderson (Dundee, United Kingdom)
The evaluation of the efficacy and safety of phospholipids‘ inhalation in patients with bronchial asthma (BA): A prospective randomized placebo-controlled study
A. Lisitsa, I. Klimanov, S. Soodaeva, A. Averyanov, O. Kuzovlev (Moscow, Russian Federation)
|  |
Onset of bronchodilation with fluticasone/formoterol versus fluticasone/salmeterol
G. Brusselle, R. Aalbers, T. McIver, B. Grothe, A. Bodzenta-Lukaszyk (Gent, Belgium; Groningen, Netherlands; Cambridge, United Kingdom; Bialystok, Poland)
| |
Intermittent versus daily inhaled corticosteroids (ICS) in children and adults with mild persistent asthma: A Cochrane review
F. Ducharme, B. Chauhan, C. Chartrand (Montreal, Canada)
| |
Oral polyunsaturated fatty acid supplementation as adjuvant therapy for asthmatic children
M. Shaheen, M. Mahmoud, D. Elshinaway (Cairo, Egypt)
| |
Does a formal prednisolone absorption test lead to improved control in difficult-to-treat asthma?
L. Midgley, J. Blakey, A. Mansur (Birmingham, United Kingdom)
| |
Patient characteristics that can predict response to omalizumab an (anti-IgE antibody) for achieving better control of asthmatic patients
N. Abdelaty (Ismailia, Egypt)
|  |
Physician assessment of asthma control in patients receiving omalizumab in a real-world setting
M. Szabo, J. Chlumsky, R. Maykut, P. Georgiou, C.W. Chen, G. Peachey (Edelény, Hungary; Prague, Czech Republic; Basel, Switzerland; Horsham, United Kingdom; East Hanover, United States Of America)
| |
Effects of inhaled corticosteroids on asthmatic inflammation: The FeNOtype trial
W. Anderson, P. Short, P. Williamson, B. Lipworth (Dundee, United Kingdom)
| |
Effects of Arg16Gly polymorphism in ADRB2 gene on responses to salmeterol or montelukast added to inhaled corticosteroids in Japanese asthmatic subjects
S. Konno, H. Makita, N. Hizawa, K. Shimizu, F. Kokubu, T. Saito, T. Endo, H. Ninomiya, H. Iijima, N. Kaneko, M. Nishimura (Sapporo, Tsukuba, Yokohama, Toukai, Higashiibaragi, Noda, Kamogawa, Japan)
| |
The efficacy of inhaled fluticasone furoate (FF) and vilanterol (VI) administered in combination in asthma is comparable when administered in the morning or evening
R. Kempsford, A. Oliver, L. Tombs, J. Bal (Stevenage, Uxbridge, United Kingdom)
| |
Efficacy of fluticasone furoate (FF) as a monotherapy and in combination with vilanterol (VI) over 12 weeks in patients with persistent asthma
E.R. Bleecker, J. Lötvall, P.M. O‘Byrne, A. Woodcock, W.W. Busse, R. Forth, H. Medley, C. Nunn, L. Jacques, E.D. Bateman (Winston-Salem, Hamilton, Madison, Research Triangle Park, United States Of America; Gothenburg, Sweden; Manchester, Uxbridge, United Kingdom; Cape Town, South Africa)
| |
Safety and tolerability of the novel inhaled corticosteroid (ICS) fluticasone furoate (FF) in combination with the long-acting beta2 agonist (LABA) vilanterol (VI) administered once daily (OD) in patients with asthma
W.W. Busse, P.M. O‘Byrne, E.R. Bleecker, J. Lötvall, A. Woodcock, L. Andersen, J. Crawford, L. Jacques, L. Apoux, E.D. Bateman (Madison, Winston-Salem, Research Triangle Park, United States Of America; Hamilton, Canada; Gothenburg, Sweden; Manchester, Uxbridge, United Kingdom; Cape Town, South Africa)
| |
Safety of once-daily QMF149 in patients with persistent asthma
R. Beasley, B. Lanier, I. Várkonyi, B. Novakova, A. Moton, H.J. Kim, B. Hederer (Wellington, New Zealand; Fort Worth, East Hanover, United States Of America; Debrecen, Hungary; Trutnov, Czech Republic; Basel, Switzerland)
| |
Is there an unmet need of small airways disease in community treated asthma?
B. Lipworth, E. Zajda, W. Anderson (Dundee, United Kingdom)
| |
Utilization of FIXED combination (FC) in the treatment of asthma patients in real life condition in the Czech Republic (UFO)
V. Kasak, E. Kasakova, J. Vinklerova (Prague, Czech Republic)
| |
Asthma exacerbation with fluticasone propionate/formoterol fumarate combination therapy versus its individual components
S. Dissanayake, M. Lomax, K. Kaiser, T. McIver (Cambridge, United Kingdom; Muttenz, Switzerland)
| |
The effect of salmeterol/fluticasone on markers of airway inflammation in patients with uncontrolled asthma
D. Tikhanov, G. Sergeeva, A. Emelyanov (Saint Petersburg, Russian Federation)
| |
Efficacy and safety of ciclesonide in the treatment of patients with persistent allergic or non-allergic asthma
O.C. Burghuber, G. Köberl, S. Lenk-Feik, M. Schantl, P. Sander, A. Hammer (Vienna, Feldkirch, Baden, Graz, Austria; Konstanz, Germany)
| |
Safety of formoterol in asthma clinical trials
M. Sears, F. Radner (Hamilton, Canada; Molndal, Sweden)
| |
Prospective follow-up of novel bone turnover markers in asthmatics exposed to low or high doses of inhaled ciclesonide over 1 year
W. Anderson, L. McFarlane, B. Lipworth (Dundee, United Kingdom)
| |